AX vs HLNE

The Advanced Deterministic Scorecard reveals a mixed financial profile: the Piotroski F-Score of 4/9 indicates borderline stable financial health, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics like a 50.8% operating margin and consistent earnings beats, weak revenue growth and lack of key financial data constrain confidence. The stock trades above the Graham Number of $88.69 at $91.75, implying a slight premium, but remains below the analyst target of $103.25. Bearish insider activity and a weak technical trend offset solid historical performance and favorable sector-relative valuation.

HLNE exhibits exceptional fundamental health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.28. While the current price of $92.28 trades at a premium to its Graham Number ($49.52) and Intrinsic Value ($71.80), it remains significantly undervalued relative to its analyst target of $155.14 and sector average P/E. The stock is currently experiencing a severe technical correction, trading near its 52-week low, which creates a compelling entry point for a company with 31.7% ROE and consistent earnings beats. The divergence between deteriorating price action and strengthening financial health suggests a high-probability reversal.